10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
The US regulator has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in certain adults with type 2 diabetes. 24 February 2020
Successful Danish biotech company Genmab (Nasdaq: GMAB) said late Friday that its chairman, Mats Pettersson, has decided to step down from the post on March 26, when his election period expires. 24 February 2020
Danish CNS specialist Lundbeck late on Friday revealed that Vyepti (eptinezumab-jjmr) has been approved by the US Food and Drug Administration for the preventive treatment of migraine in adults and will be available in April 2020. 22 February 2020
Bristol-Myers Squibb has announced the approval of Opdivo (nivolumab) for unresectable advanced or recurrent esophageal cancer in Japan. 21 February 2020
The US Food and Drug Administration has accepted for Priority Review the Biologics License Application (BLA) for the investigational AAV5 gene therapy Valrox (valoctocogene roxaparvovec) for adults with hemophilia A submitted by California-based biotech BioMarin Pharmaceutical. 21 February 2020
US health technology assessor the Institute for Clinical and Economic Review (ICER) yesterday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for cystic fibrosis. 21 February 2020
Agenus has unveiled data from pre-planned interim analyses, including for a combination of the checkpoint blocker balstilimab and the anti-CTLA-4 agent zalifrelimab. 20 February 2020
Privately-held German immune-oncology firm Immatics Biotechnologies has entered into a strategic collaboration agreement with UK pharma major GlaxoSmithKline to develop novel adoptive cell therapies targeting multiple cancer indications. 20 February 2020
Beleaguered oncology biotech Five Prime Therapeutics has been thrown a lifeline by Seattle Genetics, the antibody-drug conjugate (ADC) specialist, in the form of a global licensing agreement. 20 February 2020
USA-based FORMA Therapeutics today announced the US Food and Drug Administration has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, FT-4202, in development as a disease-modifying treatment for sickle cell disease (SCD). 20 February 2020
US biotech major Gilead Sciences announced today that Michael Quigley has joined the company as senior vice president, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology. 19 February 2020
Israeli company NeoTX, a biotech firm with a selective t-cell redirection (STR) platform for developing targeted anticancer immunotherapies, has closed a $45 million Series C financing. 19 February 2020
Australian biotech firm Immutep today announced positive interim data from its ongoing Phase II TACTI-002 study, news of which pushed its share up 14.1% to A$0.44 by close of trading. 19 February 2020
A second Phase III study from Incyte’s TRuE-AD clinical trial program in mild-to-moderate atopic dermatitis (AD) has met its primary endpoint. 19 February 2020
Shares of biotech firm Cellectis were up more than 2% at 16.09 euros by early afternoon today, after it announced the execution of a binding term sheet with fellow France-based Servier to enter into an amendment to the agreement initially signed between the two companies in 2014. 19 February 2020
The US Food and Drug Administration has awarded Priority Review status to a supplemental Biologics License Application for Tecentriq (atezolizumab) in non-small cell lung cancer (NSCLC). 19 February 2020
Belgian bioprocessing provider Univercells has received an injection of 50 million euros from Gamma Biosciences, a new investment platform supported by private equity giant KKR that is focused on technologies for the production of advanced biologic therapies including gene and cell therapies. 19 February 2020